Retina
RevOpsis raises $16.5 million to advance neovascular AMD treatment candidate
RevOpsis Therapeutics closed its first seed funding round and raised $16.5 million to advance RO-104, its lead candidate for the treatment of neovascular age-related macular degeneration.
DOJ files complaint against Regeneron for alleged false drug pricing reports
The U.S. Department of Justice filed a complaint under the False Claims Act against Regeneron Pharmaceuticals, according to a press release.
VIDEO: Iridex lasers offer continuous wave, MicroPulse treatment modalities
WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Joan Stauffer, director of marketing and communications for Iridex, discusses new laser systems from the company.
Geographic Atrophy: Recent Developments in a Rapidly Evolving Therapeutic Landscape
This activity is supported by an educational grant from IVERIC bio, Inc., an Astellas company.
nAMD and DME: Transforming Visionary Thoughts to Treatment Applications in Real-World Practice
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Ophthalmology meeting news: The biggest stories of 2024 so far
The first quarter of 2024 has come to a close, but Healio’s ophthalmology meeting news coverage is just getting started.
Opus Genetics completes dosing in first cohort of Leber congenital amaurosis trial
Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.
VIDEO: Research focuses on non-coding mutations in North Carolina macular dystrophy
WAILEA, Hawaii — In this Healio Video Perspective from Retina 2024, Kent W. Small, MD, discusses research exploring non-coding mutations in North Carolina macular dystrophy.
Retina Mythbusters: Dispelling Common Myths About the Use of Dual Inhibition Therapy Versus Anti-VEGF in Retinal Vascular Diseases
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Innovent phase 2 wet AMD treatment trial meets primary endpoint
Patients with neovascular age-related macular degeneration experienced visual benefits and anatomic improvements with extended dosing intervals of IBI302, according to a press release from Innovent Biologics.